Updated results from the ZUMA-2 trial confirmed the therapy's benefit, including in BTKi-naïve patients, after its accelerated approval in 2020.

Nodular sclerosis disease often involves mediastinal nodes and shows fibrous bands partitioning lymphoid tissue into nodules around Reed–Sternberg cells. Definitive workup requires excisional lymph ...

• BTK inhibitors are a type of targeted therapy for mantle cell lymphoma that works by blocking a specific enzyme, BTK, which is crucial for the cancer cells’ survival and spread. This interference ...

• BTK inhibitors work by targeting and blocking the BTK enzyme, which is crucial for the survival and growth of cancerous B-cells in mantle cell lymphoma (MCL). This cuts off the cancer cell’s support ...

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma, with nodal involvement being particularly uncommon. Due to its atypical clinical presentation, timely ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma Patients were enrolled in the HOVON-902 prospective cohort and received curative-intent ...

Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

To investigate this further, first author, Gabriella N. Tortorello, MD, and a research team from the University of Pennsylvania, performed a retrospective cohort study with data from the National ...

What Is Breyanzi, and Why Does It Matter? Breyanzi (lisocabtagene maraleucel) is a type of personalized cancer treatment called chimeric antigen receptor (CAR) T-cell therapy, which uses your modified ...